Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Drug Deliv ; 28(1): 2229-2240, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34668818

ABSTRACT

Fungal infections of the paranasal cavity are among the most widely spread illnesses nowadays. The aim of the current study was to estimate the effectiveness of an in situ gel loaded with voriconazole‒clove oil nano-transferosomes (VRC-CO-NT) in enhancing the activity of voriconazole against Aspergillus flavus, which causes rhinosinusitis. The nephrotoxic side effects of voriconazole may be reduced through the incorporation of the clove oil, which has antioxidant activity that protects tissue. The Box‒Behnken design was applied to formulate the VRC-CO-NT. The particle size, entrapment efficiency, antifungal inhibition zone, and serum creatinine concentration were considered dependent variables, and the soybean lecithin, VRC, and CO concentrations were considered independent ones. The final optimized formulation was loaded into a deacetylated gellan gum base and evaluated for its gelation, rheological properties, drug release profile, permeation capabilities, and in vivo nephrotoxicity. The optimum formulation was determined to be composed of 50 mg/mL lecithin, 18 mg/mL VRC, and 75 mg/mL CO, with a minimum particle size of 102.96 nm, an entrapment efficiency of 71.70%, an inhibition zone of 21.76 mm, and a serum creatinine level of 0.119 mmol/L. The optimized loaded in situ gel released 82.5% VRC after 12 hours and resulted in a 5.4-fold increase in drug permeation. The in vivo results obtained using rabbits resulted in a nonsignificant differentiation among the renal function parameters compared with the negative control group. In conclusion, nasal in situ gel loaded with VRC-CO-NT is considered an efficient novel carrier with enhanced antifungal properties with no signs of nephrotoxicity.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus flavus/drug effects , Clove Oil/pharmacology , Nanoparticles/chemistry , Voriconazole/pharmacology , Animals , Antifungal Agents/administration & dosage , Antifungal Agents/adverse effects , Antifungal Agents/pharmacokinetics , Bacterial Outer Membrane Proteins , Biomarkers , Chemistry, Pharmaceutical , Clove Oil/administration & dosage , Creatinine/blood , Dose-Response Relationship, Drug , Drug Carriers/chemistry , Drug Liberation , Gels/chemistry , Kidney Diseases/chemically induced , Liposomes/chemistry , Paranasal Sinuses/metabolism , Particle Size , Rabbits , Rheology , Voriconazole/administration & dosage , Voriconazole/adverse effects , Voriconazole/pharmacokinetics
2.
Drug Deliv ; 28(1): 229-239, 2021 Dec.
Article in English | MEDLINE | ID: mdl-33501873

ABSTRACT

PURPOSE: The work aimed to develop a co-loaded loratadine and sulpiride nasal nanoemulsion for allergic rhinitis management. METHODS: Compatibility studies were conducted adopting differential scanning calorimetry and Fourier transform infrared spectroscopy. Nanoemulsion formulations were prepared using soybean lecithin, olive oil and tween 80. Sodium cholate and glycerol were employed as co-surfactants. Nanoemulsions were assessed for viscosity, pH, droplet size, polydispersity index, zeta potential, electrical conductivity, entrapment, In vitro drug release and corresponding kinetics. Stability of the selected formulation was investigated. The biological effectiveness was evaluated in rabbit models of ovalbumin-induced allergic rhinitis by measuring TNF-α, TGF-ß and IL-1. RESULTS: Compatibility studies revealed absence of drug/drug interactions. Nanoemulsions exhibited > 90% entrapment efficiency. The selected nanoemulsion demonstrated small droplet size (85.2 ± 0.2 nm), low PDI (0.35 ± 0.0) and appropriate Zeta Potential (-23.3 ± 0.2) and stability. It also displayed enhanced in vitro drug release following the Higuashi Diffusion and Baker-Lonsdale models. The mean relative mRNA expression of TNF-α, IL-1 and TGF-ß significantly decreased from 9.59 ± 1.06, 4.15 ± 0.02 and 4.15 ± 0.02 to 1.28 ± 0.02, 1.93 ± 0.06 and 1.56 ± 0.02 respectively after treatment with the selected nanoemulsion formulation. CONCLUSION: The results reflected a promising potent effect of the combined loratadine and sulpiride nasal nanoemulsion in managing the symptoms of allergic rhinitis.


Subject(s)
Dopamine Antagonists/administration & dosage , Emulsions , Histamine H1 Antagonists, Non-Sedating/administration & dosage , Loratadine/administration & dosage , Nasal Mucosa/drug effects , Rhinitis, Allergic/metabolism , Sulpiride/administration & dosage , Surface-Active Agents , Administration, Intranasal , Animals , Calorimetry, Differential Scanning , Disease Models, Animal , Dopamine Antagonists/pharmacology , Drug Combinations , Drug Liberation , Glycerol , Histamine H1 Antagonists, Non-Sedating/pharmacology , In Vitro Techniques , Interleukin-1/metabolism , Lecithins , Loratadine/pharmacology , Nanostructures , Nasal Mucosa/metabolism , Olive Oil , Ovalbumin , Paranasal Sinuses/drug effects , Paranasal Sinuses/metabolism , Polysorbates , Rabbits , Rhinitis, Allergic/chemically induced , Sodium Cholate , Glycine max , Spectroscopy, Fourier Transform Infrared , Sulpiride/pharmacology , Transforming Growth Factor beta/drug effects , Transforming Growth Factor beta/metabolism , Tumor Necrosis Factor-alpha/drug effects , Tumor Necrosis Factor-alpha/metabolism
3.
Acta Otorhinolaryngol Ital ; 38(3): 225-228, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29984799

ABSTRACT

SUMMARY: The aim of this research is to investigate penetration of Bromelain into sinonasal mucosa in patients with chronic rhinosinusitis (CRS) versus a control group. Bromelain is derived from pineapple (Ananas comosus) and has various pharmacological effects. 40 patients (20 patients and 20 controls) were enrolled in the study. Bromelain 500 mg tablet twice daily was administered for 30 days. We scored bromelain presence in turbinate and ethmoid mucosas and in the serum of both the groups. Bromelain has an excellent distribution from blood to rhinosinusal mucosa. Its diffusion ability may allow the use of bromelain as an anti-inflammatory agent in paranasal sinus pathologies.


Subject(s)
Bromelains/blood , Bromelains/pharmacokinetics , Nasal Mucosa/metabolism , Paranasal Sinuses/metabolism , Rhinitis/metabolism , Sinusitis/metabolism , Adult , Aged , Bromelains/administration & dosage , Chronic Disease , Female , Humans , Male , Middle Aged , Rhinitis/complications , Rhinitis/drug therapy , Sinusitis/complications , Sinusitis/drug therapy , Tissue Distribution , Young Adult
4.
Eur J Pharm Sci ; 96: 499-507, 2017 Jan 01.
Article in English | MEDLINE | ID: mdl-27771516

ABSTRACT

Mucoadhesive in situ gelling systems (soluble gels) have received considerable attention recently as effective stimuli-transforming vectors for a range of drug delivery applications. Considering this fact, the present work involves systematic formulation development, optimization, functional evaluation and ex vivo performance of thermosensitive soluble gels containing dexamethasone 21-phosphate disodium salt (DXN) as the model therapeutic. A series of in situ gel-forming systems comprising the thermoreversible polymer poloxamer-407 (P407), along with hydroxypropyl methyl cellulose (HPMC) and chitosan were first formulated. The optimized soluble gels were evaluated for their potential to promote greater retention at the mucosal surface, for improved therapeutic efficacy, compared to existing solution/suspension-based steroid formulations used clinically. Optimized soluble gels demonstrated a desirable gelation temperature with Newtonian fluid behaviour observed under storage conditions (4-8°C), and pseudoplastic fluid behaviour recorded at nasal cavity/sinus temperature (≈34°C). The in vitro characterization of formulations including rheological evaluation, textural analysis and mucoadhesion studies of the gel form were investigated. Considerable improvement in mechanical properties and mucoadhesion was observed with incorporation of HPMC and chitosan into the gelling systems. The lead poloxamer-based soluble gels, PGHC4 and PGHC7, which were carried through to ex vivo permeation studies displayed extended drug release profiles in conditions mimicking the human nasal cavity, which indicates their suitability for treating a range of conditions affecting the nasal cavity/sinuses.


Subject(s)
Chitosan/metabolism , Drug Delivery Systems/methods , Hypromellose Derivatives/metabolism , Nasal Mucosa/metabolism , Poloxamer/metabolism , Temperature , Animals , Chemistry, Pharmaceutical , Chitosan/administration & dosage , Chitosan/chemistry , Drug Evaluation, Preclinical/methods , Gels , Humans , Hypromellose Derivatives/administration & dosage , Hypromellose Derivatives/chemistry , Mucous Membrane/drug effects , Mucous Membrane/metabolism , Nasal Mucosa/drug effects , Organ Culture Techniques , Paranasal Sinuses/drug effects , Paranasal Sinuses/metabolism , Poloxamer/administration & dosage , Poloxamer/chemistry , Solubility , Swine
5.
Expert Rev Clin Immunol ; 10(9): 1133-5, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25081306

ABSTRACT

More than 300 million individuals in industrialized countries suffer from allergic rhinitis. Rhinitis is a disease characterized by stuffy or runny nose, followed by red, itchy watering eyes and repeated sneezing. But more common problems for rhinitis patients are the overlooked social difficulties, with the majority reporting tiredness, feeling miserable or irritable. Often, medication is not able to adequately control symptoms and there is a need for other aids against the disease. Here, we describe the current situation after five trials using nasal filters in the remediation of seasonal allergic rhinitis.


Subject(s)
Air Filters/statistics & numerical data , Paranasal Sinuses/metabolism , Rhinitis, Allergic, Seasonal/therapy , Allergens/immunology , Antigens, Plant/immunology , Clinical Trials as Topic , Humans , Paranasal Sinuses/immunology , Plants , Pollen/immunology
6.
Clin Biochem ; 35(5): 369-75, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12270766

ABSTRACT

BACKGROUND: The role of cytokines and reactive oxygen species formation in the pathogenesis of chronic sinusitis is still not fully understood. This work was designed to determine if patients with chronic sinusitis demonstrate altered levels of serum IL-12 and/or tissue antioxidants. SUBJECTS AND METHODS: Mucosal biopsy specimens from the uncinate process of patients with chronic sinusitis were obtained from 52 patients using functional endoscopic sinus surgery. Normal mucosa samples were collected from 20 healthy controls. Patients' group was further classified according to computerized tomography findings into mild and severe subgroups. Serum IL-12 was estimated using enzyme immunoassay (EIA). The levels of tissue uric acid, and reduced glutathione were determined biochemically, alpha-tocopherol was measured by HPLC. Superoxide dismutase (SOD) activity was determined by spectrophotometry. RESULTS: A significant decrease in serum IL-12, tissue alpha-tocopherol and SOD in patient group was demonstrated (p < 0.05). Tissue uric acid and reduced glutathione showed primary increase in mild subgroup followed by significant drop in severe subgroup (p < 0.05). Negative significant correlation was observed between glutathione, uric acid, and SOD, and the severity of the disease (p < 0.05) independent of the cellularity of the biopsy. CONCLUSION: The presented data suggests a possible role of IL-12, and tissue antioxidants in development and progression of chronic sinusitis. Adjuvant antioxidant treatment may have role in achieving better prognosis of the disease.


Subject(s)
Antioxidants/analysis , Interleukin-12/blood , Sinusitis/blood , Sinusitis/metabolism , Chromatography, High Pressure Liquid , Chronic Disease , Female , Glutathione/analysis , Humans , Male , Paranasal Sinuses/chemistry , Paranasal Sinuses/enzymology , Paranasal Sinuses/metabolism , Reactive Oxygen Species/analysis , Superoxide Dismutase/metabolism , Uric Acid/analysis , alpha-Tocopherol/analysis
SELECTION OF CITATIONS
SEARCH DETAIL